New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:39 EDTABBV, ENTAEnanta Pharmaceuticals says starting FY14 with 'strong' cash position
The company said, “Enanta (ENTA) is beginning FY14 with a strong cash position and four compounds in the clinic. Our partner AbbVie (ABBV) recently completed the largest phase 3 program to date for an all-oral, genotype 1 hepatitis C virus treatment regimen, and it expects to launch the regimen in FY14. AbbVie’s tested regimen includes our collaboration’s lead protease compound ABT-450. In addition, we continue to explore new infectious disease areas and have recently initiated a phase 1 study of our proprietary bicyclolide candidate EDP-788 which we are developing for MRSA.”
News For ENTA;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:33 EDTENTAEnanta appoints Nathalie Adda as SVP, chief medical officer
Enanta Pharmaceuticals (ENTA) announced the appointment of Nathalie Adda, M.D., as senior VP and chief medical officer, responsible for clinical and regulatory affairs. Most recently, Adda was chief medical officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene (TRNG), where she led the Oncology and Infectious Disease programs since 2012.
07:32 EDTABBVJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 26, 2015
12:02 EDTABBVEMA adopts positive opinion on AbbVie's Humira for acne inversa
Subscribe for More Information
June 24, 2015
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information
June 22, 2015
08:56 EDTENTAEnanta management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use